Posted by Michael Wonder on 08 Dec 2023
Alpha Cognition announces FDA acceptance of new drug application for ALPHA-1062 for mild to moderate Alzheimer’s disease
7 December 2023 - Alpha Cognition is pleased to announce that the US FDA has completed its filing review and has accepted the company’s new drug application for ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease.
The new drug application has been granted a Prescription Drug User Fee Act goal date of 27 July 2024.
